MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
Palatin Technologies Interest Expense 2011-2026 | PTN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Palatin Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 K | 17.1 K | 20 K | 29.7 K | 23.4 K | 20.1 K | 418 K | 1.45 M | 1.45 M | 2.51 M | 662 K | 6.21 K | 8.41 K | 10.4 K | 10.6 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.51 M | 6.21 K | 444 K |
Quarterly Interest Expense Palatin Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.7 K | 2 K | - | 1.8 K | 169 K | 5.94 K | - | 1.25 K | 1.6 K | 10.9 K | - | 3.43 K | 5.49 K | 9.6 K | 15.1 K | 3.02 K | 2.77 K | 5.63 K | 8.4 K | - | 1.87 K | 7.49 K | 1.87 K | 7.49 K | 2.5 K | 9.05 K | 2.5 K | 9.05 K | 92.3 K | 207 K | 92.3 K | 207 K | 391 K | 457 K | 391 K | 457 K | 595 K | 624 K | 595 K | 624 K | 629 K | 628 K | 629 K | 628 K | 31.9 K | 1.73 K | 31.9 K | 1.73 K | 954 | 1.85 K | 954 | 1.85 K | 1.36 K | 2.28 K | 1.36 K | 2.28 K | 1.85 K | 2.97 K | 1.85 K | 2.97 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 629 K | 954 | 137 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Scholar Rock Holding Corporation
SRRK
|
-301 K | $ 43.62 | -1.33 % | $ 5 B |  USA |
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | USA |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | USA |
 |
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Stoke Therapeutics
STOK
|
9 K | $ 33.98 | 0.83 % | $ 2.01 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.23 | -5.04 % | $ 314 M |  Britain |
 |
EyePoint Pharmaceuticals
EYPT
|
11.8 M | $ 13.09 | 0.23 % | $ 959 K | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
China SXT Pharmaceuticals
SXTC
|
1.62 M | $ 1.38 | 4.55 % | $ 1.96 M | China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
131 B | $ 18.16 | 0.55 % | $ 28.4 B |  Japan |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
874 K | $ 1.07 | -2.29 % | $ 21.9 M |  Israel |
 |
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | USA |
 |
Equillium
EQ
|
-76 K | $ 2.06 | - | $ 118 M | USA |
 |
Theravance Biopharma
TBPH
|
10.2 M | $ 14.97 | -1.45 % | $ 753 M | Cayman-islands |
 |
Eton Pharmaceuticals
ETON
|
955 K | $ 23.43 | -0.09 % | $ 630 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 47.18 | -0.79 % | $ 4.24 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.46 | 0.22 % | $ 855 M |  Canada |
 |
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | USA |